Compugen Reports Second Quarter 2026 Results
Compugen reported Q2 2026 revenue of $2.6 million, doubling from $1.3 million in the prior year, driven by milestone payments from partner Gilead. Net loss narrowed slightly to $7.0 million, or $0.07 per share, while cash, cash equivalents, and investments totaled $125.3 million, providing a runway into 2029. Operationally, the MAIA-ovarian trial for COM701 remains on track for an interim analysis with median PFS data expected by Q1 2027. Partner AstraZeneca presented the first overall survival readout for rilvegostomig, showing 16.8 months in first-line biliary tract cancer, and initiated an additional Phase 3 trial.
Key figures
- Revenue
- $2.6 million
- Revenue Yoy
- 100%
- Net loss
- $7.0 million
- Cash runway
- into 2029
- Ga expenses
- $2.3 million
- Cash balance
- $125.3 million
- Rnd expenses
- $6.3 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.